James Turkson, PhD (Chair of Cytokines 2022 in Hawaii)
Professor, Department of Medicine, Division of Medical Oncology
Associate Director of Strategic Partnerships
Cedars-Sinai Medical Center, Los Angeles, CA USA [READ MORE]
Wei Chen, PhD
Postdoctoral Fellow
NIH/NCI
Rockville, MD USA [READ MORE]
Kristina Adams Waldorf, MD
Professor, Obstetrics & Gynecology and Global Health
UW Medicine, Seattle, WA USA [READ MORE]
De’Broski R. Herbert PhD
Associate Professor of Immunology
University of Pennsylvania, PennVet
Philadelphia, PA USA [READ MORE]
Rebecca Porritt, PhD
Research Scientist I, Department of Pediatrics and Biomedical Sciences
Assistant Professor of Pediatrics, UCLA School of Medicine
Cedars-Sinai Medical Center, Los Angeles, CA, USA [READ MORE]
Moshe Arditi, M.D.
Executive Vice-Chair, Department of Pediatrics for Research
Professor of Pediatrics, Cedars Sinai Medical Center and UCLA School of Medicine
Director, Division of Pediatric Infectious Diseases and Immunology,
Director, Infectious and Immunologic Diseases Research Center (IIDRC), Department of Biomedical Science, Cedars Sinai Medical Center, Los Angeles, CA, USA [READ MORE]
Reviews of Interest to cytokine biologists. [READ MORE]
Reviews of interest related to COVID-19 and cytokine biology [READ MORE]
By Marta Catalfamo Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc) ClinicalTrials.gov Identifier: NCT05080790 Contact: Daniel Pink, Dr. 033631 73527 [email protected] Contact: Melanie Prause 069 7601 4211 [email protected] Sponsors and Collaborators Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest EUSA Pharma, Inc. [READ MORE]
Early in the COVID-19 pandemic, several groups of scientists proposed IFN- as a potential therapy for SARS-CoV-2 infection (O’Brien et al., Clinical Infectious Diseases, 2020; Prokunina-Olsson et al., Journal of Experimental Medicine, 2020). That suggestion was based on evidence that the IFN- family provides important first-line immunological defense against viral respiratory tract infections and data indicating that SARS-CoV-2 induces weak expression of IFNs. There are no licensed IFN- therapeutics, however, pegylated-interferon lambda 1, which was shown to be safe and effective in testing among >3,000 patients with chronic viral hepatitis infections, is available as an investigational agent through Eiger Biopharmaceuticals. Several phase 2 clinical trials have been launched to assess the safety and efficacy of pegylated-IFN-1 for treatment or prevention of SARS-CoV-2 / COVID-19. Findings from two trials are now available. [READ MORE]
International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy
